Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thymosins are a family of small, biologically active peptides originally isolated from the thymus gland that function as critical regulators of the immune system and mediators of tissue regeneration. The two most prominent members, Thymosin alpha-1 (T\u03b11) and Thymosin beta-4 (T\u03b24), serve distinct therapeutic roles. T\u03b11 is a potent immunomodulator that promotes T-cell differentiation and maturation, making it an effective treatment for chronic viral infections like Hepatitis B and C, and a potential adjuvant in cancer immunotherapy to enhance the body's anti-tumor response [NIH, StatPearls]. Conversely, T\u03b24 is the major actin-sequestering molecule in eukaryotic cells, playing a pivotal role in maintaining the cytoskeleton and promoting cell migration. Its ability to accelerate wound healing and reduce inflammation has led to its investigation for treating corneal injuries, skin wounds, and cardiac repair following myocardial infarction [PubMed]. Because thymosins are naturally occurring peptides, they generally exhibit a high safety profile with low toxicity, making them attractive candidates for complex multi-systemic conditions involving both immune dysfunction and tissue damage.
Thymosin alpha-1 acts as a Toll-like receptor (TLR) 9 and TLR2 agonist in myeloid dendritic cells, leading to the activation of nuclear factor kappa B (NF-κB) and the subsequent production of type I interferons and proinflammatory cytokines, which enhances T-cell and Natural Killer (NK) cell activity [PMID: 23641113, NIH]. Thymosin beta-4 functions primarily by binding to and sequestering G-actin in a 1:1 ratio, preventing its polymerization into F-actin, which facilitates cell motility, suppresses inflammation, and promotes tissue repair and angiogenesis [PMID: 17466850, UniProt].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thymosin (TMS).